Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.

Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol. 2011 Apr 01; 29(10):1349-55.

View in: PubMed

subject areas

Antibodies, Monoclonal, Murine-Derived
Antineoplastic Combined Chemotherapy Protocols
Cytogenetic Analysis
Disease-Free Survival
Genes, Immunoglobulin Heavy Chain
Humans
Kaplan-Meier Estimate
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Myeloid, Acute
London
Mutation
Proportional Hazards Models
Risk Assessment
Risk Factors
Rituximab
Survival Rate
Time Factors
Treatment Outcome
United States
Vidarabine

authors with profiles

Richard A. Larson